News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden New US Cholesterol Guidelines: The good, the bad and the ugly Inclisiran effective in patients with polyvascular and cerebrovascular disease ESC 2021 Inclisiran in polyvascular disease UK NICE approves use of inclisiran: a gamechanger for patients and the NHS HUYGENS reinforces the importance of intensive lipid lowering after ACS ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?Alirocumab safe in patients with diabetes mellitus

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Question of the Month

Combination therapy in familial hypercholesterolaemia: what can we gain from novel agents?

LDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH?
Professor John Chapman

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »

News from the Trials

Keep up to date with latest news and analyses from PCSK9 inhibitor trials.

View latest news »

Trial Resources

For expert analysis and insights

View Trials »

View Trial slide decks »

Most viewed

Treating high risk cardiovascular disease: Is combination lipid lowering therapy now the rule not the exception? HUYGENS reinforces the importance of intensive lipid lowering after ACS Huygens: Does PCSK9 inhibition impact the vulnerable plaque? Inclisiran effective in patients with polyvascular and cerebrovascular disease How do clinicians translate intensive LDL-C lowering to their practice? Low lipoprotein(a): Is there any potential risk? How to diagnose statin intolerance? News from ODYSSEY OUTCOMES: Lipoprotein(a) and diabetes risk UK NICE approves use of inclisiran: a gamechanger for patients and the NHS HUYGENS: How does PCSK9 inhibition impact plaque phenotype?

Most viewed

Treating high risk cardiovascular disease: Is combination lipid lowering therapy now the rule not the exception?

Hot Topics

14th Closed Virtual Meeting of the Editorial Board of PCSK9 Forum

PCSK9 inhibition: The evolving treatment paradigm post-MI

Lowering of guideline-recommended LDL-C goals in the post-MI setting has implications for real-world practice. Here, PCSK9 Forum Editors discuss cases, using evidence from ODYSSEY OUTCOMES and FOURIER.

Prof Gregory Schwartz uses data from ODYSSEY OUTCOMES to support management strategies.

Watch now

Prof Robert Giugliano discusses evidence from FOURIER in the context of managing FH patients.

Watch now

From the Editors

Proof-of-concept: Gene-editing for PCSK9 inhibition

Prof. John Chapman, Pitié-Salpêtrière University Hospital, Sorbonne University, and National Institute for Health and Medical Research (INSERM), Paris, France.

Read the report

Other related reports:

DA-VINCI: Need to do better with LDL cholesterol management in practice in Europe

Pooled analysis highlights the promise of inclisiran

Inclisiran: Update on efficacy, dosing regimen, safety and COVT trial

Very low lipoprotein(a) and very low LDL cholesterol – are they safe?